advancing the business of biotechnology and life scienceELECTRICITIES Proven, Comprehensive Economic...

BIO 2011 Special Edition Vol. 3, Issue 3

advancing the business ofbiotechnology and life science

2 www.ncbiotech.org BIO 2011

Platinum Sponsors

Gold Sponsors

Silver Sponsors

Special Thanks to the sponsors of the North Carolina Pavilion (#3519)

NC PAVILION SPONSORS

Bronze SponsorsAldagen

Biltmore FarmsBiofuels Center of NC

BioResource InternationalBusiness NC Magazine

CEDCempra Pharmaceuticals

Chelsea TherapeuticsClinical Ink

Duke EnergyDuke Medicine

Duke Translational Research InstituteExpression Analysis

Flow SciencesImpact Magazine

KBILeChase Construction

Murgitroyd

NCNE CommissionNovare Biologistics

NovozymesO’Brien/Atkins

On Assignment Clinical ResearchPappas Ventures

Parker PoePinehurst Resort

Quintiles

RTIRTP

SPRI Clinical TrialsSynereca

Wake Forest University Baptist Medical CenterWomen in Bio

Wyrick Robbins Yates & Ponton LLP

BIO 2011 www.readimpact.com 3

We mean that North Carolina has everything that life science companies need to grow and prosper, starting with a record of success that’s earned the state national and international recognition as a life science leader.

North Carolina’s package contains 538 life science companies, small and large, that are making discoveries and turning them into products involving:

But these are only components of the package.

North Carolina also has a network of seven research parks, including the internationally recognized Research Triangle Park, attracting many of our life science companies.

Innovation is driven in North Carolina by the 16-campus University of North Carolina system and by leading private universities such as Duke, Campbell and Wake Forest. Through basic research, academic and industry partnerships and technology transfer, the universities are contributing to new ways to prevent and treat disease, improve crops and fi nd new sources for fuel.

There’s still more to North Carolina’s life science package. Our companies and institutions

have critical expertise in testing and clinical trials readily available through the state’s Contract Research Organizations (CROs) – the world’s largest concentration, appropriately including the headquarters of the sector’s leading companies.

Companies are further bolstered by the North Carolina Biotechnology Center that makes connections between academia, industry and government, and by NCBIO, the state’s chapter of the Biotechnology Industry Organization.

As a bonus, North Carolina is unequaled in workforce training and education at every level from doctoral, master’s and bachelor’s programs to two-year associate degrees and professional development courses. The state is also rife with support industries. Law fi rms specialize in intellectual property. Construction fi rms understand the requirements of laboratory space. Venture capital and angel investors assist with the fi nancial needs of growing companies. Other companies supply qualifi ed staff, research tools, laboratory equipment, specialized janitorial services and every other product and service life science companies need to be successful.

The ribbon that ties our life science package together is that North Carolina leaders – government, business and academic – are committed to advancing the state’s unparalleled business environment that is tailor-made for ideas and innovation to fl ourish. An environment built on a 30-year investment in the biosciences that has returned an economically powerful and diverse industry.

Now, add to that North Carolina’s beaches, mountains, sports, international cuisine, cultural attractions, reasonable cost of living, friendly people and mild four-season climate, and it’s easy to see why we have

What do we mean by the complete package?

Advanced Medical Technologies

Agriculture

Biofuels

Biomanufacturing

Human Health

Marine Biotechnology

Nanobiotechnology

Nutrition and Nutraceuticals

Pharmaceuticals

Regenerative Medicine

Vaccines

North Carolina Life Sciences

THE COMPLETE PACKAGE

page 12

page 16

AgBiotech

HumanHealth

page 32

Technology

page 44

Support

Vaccinespage 8

page 26

Biomanufacturing

– the complete life – and life science – package!


The Complete Package >Table of ContentsThe Complete Life Science Package North Carolina: The Complete Package 3

Biotechnology Thrives Across North Carolina 6

Vaccines: At the Center of the Vaccine Industry 8

AgBiotech: Boosting Agriculture with Biotech 12

Human Health: Leading Cancer Research and Treatment 16

Power of the Parks 18

Biomanufacturing: NC Re-Invents ‘Factory’ Jobs 26

Emerging Technologies: All the Right Ingredients 32

Support: Build, Test, Market and Protect 44

Sponsors GLAXOSMITHKLINE Forward Thinking 9

MEDICAG0 USAExciting, Emerging VaccineTechnologies 11

NORTH CAROLINA’S AGRICULTURAL BIOTECHNOLOGY INITIATIVE 13

BAYER CROPSCIENCEA Global Leader in Agriculture 14

BASF PLANT SCIENCE Approaching Agricultural Challenges with Biotechnology Innovations 15

THE UNIVERSITY OF NORTH CAROLINALeading the State in Biotechnology Discovery and Translation 20

NC RESEARCH CAMPUSEmerging, Thriving, Leading 21

NORTH CAROLINA DEPARTMENT OF COMMERCEA State of Innovation and Investment 22

NORTH CAROLINA BIOTECHNOLOGY CENTERMaking Connections That Make Biotechnology Grow 28

RESEARCH TRIANGLE REGIONAL PARTNERSHIP Concentrated Life Science Expertise, High-Level Innovation 30

SYNGENTAOffering Solutions for Sustainability in Agriculture 31

BIOMANUFACTURING TRAINING AND EDUCATION CENTERProviding a Range of Services to the Biomanufacturing Industry and Enhancing Economic Development 34

NC COMMUNITY COLLEGE SYSTEMOne Step to a Biotech Career 35

PIEDMONT TRIAD PARTNERSHIPThe Right Place for Life Science Companies 36

DSMLong-Term Total Value to Customers 37

WEST PHARMA Resources for Biopharmaceutical Risk Mitigation 38

SCYNEXIS, INC. From Concept to Clinic with Speed and Innovation 39

ELECTRICITIESProven, Comprehensive Economic Development Solutions 41

YONKERS INDUSTRIESThriving on Adaptability and Flexibility 42

TALECRIS BIOTHERAPEUTICS, INC.Hope for Patients with Rare, Life-Threatening Diseases 43

NC Pavilion MapFind Out More about North Carolina’s Complete Life Science Package, visit the NC Pavilion 24

AdvertisementsBiltmore Park Town Square 4

Novartis Vaccines 10

The Hamner Institutes for Health Services 10

NCBIO 10

MARBIONC 13

Inspire Pharmaceuticals 15

Biogen Idec 15

North Carolina Arboretuem/Bent Creek Institute 17

Nagoya University 17

Jenkins, Wilson, Taylor & Hunt 22

SEBIO 29

COIN 33

BioNetwork 35

NCBioImpact 35

SAS 36

Targacept 36

Forma Life Science Marketing 37

BioTechLogic 37

PSNC Energy 38

iBiotech, Inc. 38

Kymanox 39

Womble Carlyle Sandridge & Rice 39

Hockmeyer 40

Smith Anderson 40

Coats+Bennett 41

TBSI 41

BioEast Alliance 42

Shepherd Research 42

Treyco/Global Future Solutions 43

BE&K Building Group 43

MethodSense 45

Impact Magazine 46

Pinehurst 47


North Carolina Life Sciences >

Biotechnology Thrives Across North Carolina

Regional Spotlight

W ernWesternW n

PiedmoPieddP dmPiedTriadrr

GreaterGreGreaaCharlotteChaarlooarllotte

DAVIDSON

DAVIE

FORSYTH GUIL

MONTGOMERY

RANDOL

ROCKINGSTOKESSURRY

YADKIN

ANSON

CABARRUS

CATAWBA

GASTON

IREDELL

LINCOLN

MECKLENBURG

RIC

ROWAN

STANLY

UNION

ALEXANDER

ALLEGHANYASHE

AVERY

BUNCOMBE BURKE

CALDWELL

CHEROKEECLAY

CLEVELANDGRAHAM

HAYWOOD

HENDERSON

JACKSON

MCDOWELL

MACON

MADISON

MITCHELL

POLK

RUTHERFORDSWAIN

TRANSYLVANIA

WATAUGA WILKES

YANCEY

Winston-Salem

Asheville

Charlotte

NUTRITION AND HEALTH RESEARCH

At the $1.5 billion NC Research Campus in Kannapolis, teams of top scientists from North Carolina universities and industry collaborate to further advancementsin biotechnology, nutrition and health.

•

MARINE BIOTECHNOLOGYRich with natural and economic development assets, the Southeastern region is commercializing products from marine biotechnology.

NATURAL PRODUCTS

The Bent Creek Institute laboratories at the NC Arboretum in Asheville conduct research in plant sciences and house the only repository of medicinal-plant germplasm in North America.

•

REGENERATIVE MEDICINEThe Piedmont Triad area is leading the world in regenerative medicine through the ground-breaking work of Dr. Tony Atala at the Wake Forest Institute for Regenerative Medicine.

•

phot

o: B

ent

Cree

k In

stit

ute

phot

o: W

ake

Fore

st I

nsti

tute

fo

r Re

gene

rati

ve M

edic

ine

phot

o: N

orth

Car

olin

a Re

sear

ch C

ampu

s

photo: Jamie Moncrief / UNCW


The Complete Package

onttd EasternsternnasternEa

Researchs a hTriangleriTT iiangg

Southeasternsterneastoutheao

NEW HANOVERNEW HANOVER

BLADEN

BRUNSWICK

COLUMBUS

CUMBERLAND

DUPLINHOKE

ONSLOW

PENDER

ROBESON

SAMPSON

SCOTLAND

BEAUFORT

BERTIE

CAMDEN

CHOWAN

CRAVEN

CURRITUCK

DARE

EDGECOMBE

GATES

GREENE

HALIFAXHERTFORD

HYDE

JONES

LENOIR

MARTIN

NASH

NORTHAMPTON PASQUOTANKPERQUIMANS

PITT

TYRRELLWASHINGTON

WAYNE

WILSONCHATHAM

DURHAMFRANKLIN

GRANVILLE

HARNETT

JOHNSTONLEE

MOORE

ORANGE

PERSON VANCE

WAKE

WARREN

ALAMANCE

CASWELL

FORD

Y

LPH

GHAM

CHMOND

Greenville

Wilmington

Raleigh

RTP

VACCINES Novartis Vaccines’ $1 billion, 430,000-square-foot, cell-culture-based manufacturing facility in Holly Springs will produce hundreds of millions of fl u vaccines.

••

AGBIOTECH

The Eastern region of North Carolina, known for agricultural biotechnology, is home to Avoca, Inc., North America’s largest extraction facility for the production of sclareol from clary sage.

•

phot

o: A

voca

photo: Novartis

Vaccines are not just for children any more. Scientifi c and technological advances are making it possible for vaccines to move beyond childhood diseases to tackle adolescent and adult diseases. From infl uenza, cervical cancer and HIV/AIDS to tuberculosis and malaria, vaccines are increasingly essential to the prevention of diseases worldwide. With companies, research universities and specialized workforce training programs, North Carolina is at the center of the global vaccine industry.

NC Vaccine CompaniesNovartis Vaccines and Diagnostics, Inc. is investing

$1 billion in a 430,000-square-foot facility in Holly Springs near the Raleigh-Durham area and the state’s renowned Research Triangle Park. The facility, which is partially supported by a 2009 contract from the Biomedical Advanced Research and Development Authority (BARDA), is the fi rst US cell-based vaccine manufacturing facility for seasonal and pandemic fl u. When it is fully operational in 2013, BARDA reports that the US capacity to respond to pandemic infl uenza will increase by at least 25 percent.

Novartis is only one global pharmaceutical company that calls North Carolina home. Merck & Co., GlaxoSmithKline and Pfi zer fi ll out this roster. One of the most exciting new additions is the $42-million Medicago vaccine plant under construction in Research Triangle Park, to grow virus-like particles in tobacco leaves. In total, North Carolina has 32 companies, from global leaders to biotech start-ups, that are researching and developing vaccines, giving North Carolina one of the nation’s largest vaccine clusters.

WorkforceBy employment

and number of manu-facturing facilities, North Carolina has the largest concentration of vaccine manufacturers. As reported in The Vaccines Market Outlook to 2014 (Business Insights, July

2009), 17.4 percent of all people employed in vaccine manufacturing in 2009 worked in North Carolina.

Delivering a workforce to support the pharmaceutical and biomanufacturing industry is possible because of the state’s long-term investment in workforce training. NCBioImpact, a consortium of state leaders and educational institutions, established the Golden LEAF Biomanufacturing Training and Education Center (BTEC), NC Central University’s Biomanufacturing Research Institute and Technology Enterprise (BRITE) and the NC Community College’s BioNetwork.

University Research Medical schools at Duke University, UNC at Chapel Hill,

Wake Forest University and East Carolina University, plus the veterinary school at NC State, offer research partnerships and opportunities for technology transfer that can enhance vaccine development. The research capabilities of the universities are augmented by research institutions like the Hamner Institutes for Health Sciences and RTI International. In 2009, North Carolina researchers, private and public, attracted $111 million in NIH funding for vaccine-related research. In 2008, federal contracts for vaccines totaled $1.5 billion.

A concentration of companies, researchers and trained workers put North Carolina in the center of the vaccine industry and its critical role in preventing disease and promoting better health worldwide.

w w w . n c b i o t e c h . o r g / v a c c i n e s

At the Center of the Vaccine Industry

Photo Courtesy of Biogen Idec, Inc.

Photo Courtesy of Biogen Idec, Inc.



The pharmaceutical industry is experiencing a time of unprecedented challenge. GlaxoSmithKline (GSK) is leading the industry with forward thinking that directly addresses the challenges.

The company is striving to build one of the strongest pipelines in the industry and transform the way it does research and development with the goal of ensuring delivery of GSK’s current pipeline but also delivering a sustainable fl ow of new products for years to come. A key strategy that underpins this quest is externalisation. GSK’s Worldwide Business Development team is leading this effort and is the driving force behind the spirit of Forward Thinking.

Forward Thinking embodies the agility and vision required to adapt quickly and to succeed in the 21st century. It enables GSK to successfully pioneer and deliver new and innovative medicines through collaborations with like-minded companies. GSK’s research and development organization has embraced Forward Thinking throughout. For example, in 2008, there were 34 external research engines in the GSK research and development network. Today, the number is 47. The growth is due in part to GSK’s industry leadership in forming a broad range of collaborations and deal structures. GSK has a strong track record, and over the past eight years the company has signed more late-stage collaborations than anyone else in the industry.

GSK is committed to collaborations that can expand its business in emerging markets as well. The Asia Pacifi c, Japan and Emerging Markets (APJEM) R&D Group represents a new business model in GSK comprised of experts dedicated to building a pipeline of medicines specifi cally for emerging markets. The goal is to harness the potential in emerging markets, encompassing all aspects from products to R&D to branded generics.

Forward Thinking is about encouraging diverse approaches and nurturing an innovative spirit. It’s about true partnership and tapping into research teams with a fundamentally different

thought process to increase the probability of success. The result, approximately 30 percent of GSK’s discovery research is externalized.

GSK believes that Forward Thinking can lead to the best science. The foundation for discovering and developing the best science is rooted in the quality of the relationship. GSK’s Business Development team encourages early and frequent contact with partners or potential partners. The Business Development team is experienced at building progressive external relationships that cross numerous therapeutic areas, specifi cally cardio-vascular and metabolic, immune-infl amation, infectious diseases, oncology, biopharmaceuticals and respiratory.

From discovery through development, Forward Thinking is quality science backed by a commitment to innovative, external collaborations that accelerate drug development and fulfi ll GSK’s mission of enabling people to do more, feel better and live longer.

JOIN GSK IN FORWARD THINKING.

GLAXOSMITHKLINE

Forward Thinking

w w w . g s k . c o m / c o l l a b o r a t i o n s / b u s i n e s s d e v . h t m

“Forward Thinking is about encouraging diverse

approaches and nurturing an innovative spirit.”

Aerial view of the GSK Research Triangle Park, NC campus

North Carolina Life Sciences >The Complete Package

www.novartis.com/careers

Inspiring science. Delivering hope.

http://ncbioscience.net

At The Hamner, our mission is to create

a multidisciplinary campus that catalyzes

innovative technology development and

breakthroughs in biomedical science.

Building on more than 35 years of distinction

in public health and environmental sciences

research, scientists at The Hamner conduct

preeminent research in chemical and drug

safety and play a pivotal role in improving

human health.

Please visit our website to learn more:

www.thehamner.org


Innovation is the Best MedicineBreakthrough medicines are our highest priority – they open up healthcare’s frontier and answer unmet needs.

But no two patients are exactly alike. That’s why at Novartis we go beyond breakthrough medicines to offer disease prevention, generic alternatives and access to medicines.

In late 2009 NVD opened its large scale Flu Cell Culture and adjuvant manufacturing facility in Holly Springs, NC where a winning team and culture thrive in a state-of-the-art and model vaccine manufacturing facility – one of the fi rst in the US. Think What’s Possible

Medicago is a clinical-stage biotechnology company, developing effective and competitive vaccines based on proprietary Virus-Like Particles (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against pandemic and seasonal infl uenza using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identifi cation and reception of the genetic sequence. This production time frame has the potential to allow vaccination of the population before the fi rst wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market.

Medicago has developed the Profi cia® technology, a proprietary alternative to traditional egg-based and cell production systems. Using whole living plants as hosts, the Profi cia® technology is rapid, fl exible, high yielding and a robust vaccine and antibody production system. To produce effective vaccines, Medicago combines its innovative Profi cia® manufacturing technology to the Virus-like particles (VLPs), which represent one of the most exciting emerging vaccine technologies for generating effective and long-lasting protection. VLPs mimic the native structure of a virus, allowing them to be recognized readily by the immune system. However, they lack the core genetic material, making them non-infectious and unable to replicate. A key advantage of VLPs allows them to more effectively activate key aspects of the immune response to achieve potent immune stimulation and foster immunological memory. Medicago’s VLP technology is currently being used to develop infl uenza vaccines and other vaccines against diseases of worldwide interest.

During the H1N1 infl uenza outbreak in 2009, Medicago’s rapid plant-based process was able to successfully develop a vaccine candidate in less than a month after identifi cation of the H1N1 strain, compared to six months for the development of a vaccine using traditional egg-based methods.

In August 2010, Medicago USA Inc. was awarded a $21 million grant from the Defense Advanced Research Projects Agency (DARPA) to demonstrate the scalable manufacturing of its plant-expressed VLP vaccines in the US under a Technology Investment Agreement. This DARPA

project is an accelerated and integrated effort to deliver effective production of pandemic infl uenza in the US.

Medicago USA, a wholly owned subsidiary of Medicago Inc., has commenced the construction of its cGMP facility in Research Triangle Park (RTP), NC. This vaccine facility will include a fully automated greenhouse and a state-of-the-art extraction and purifi cation unit. The 97,000-square-foot cGMP facility will have the capacity to produce more than 40 million doses of seasonal infl uenza vaccine or 120 million doses of pandemic infl uenza vaccine a year. The vaccine facility is scheduled to be complete this year.

Medicago is currently developing pandemic and seasonal infl uenza vaccine candidates. Its pandemic H5N1 infl uenza VLP vaccine successfully completed Part A of a Phase II human clinical trial in February 2011. The vaccine was found to be safe, well tolerated and also induced a solid immune response. In the second part of the study, 120 healthy adults will receive an injection of either the H5N1 vaccine at the optimal dose or a placebo. Final results are currently expected in the second quarter of 2011.

Medicago has also received US Food and Drug Administration clearance to initiate its Phase I H1N1 infl uenza VLP vaccine candidate (H1N1 vaccine) clinical trial in the US. This Phase I trial will lead into Medicago’s US Phase IIa trial for its seasonal trivalent vaccine with the recommended H1N1, H3N2 and B infl uenza strains which the company plans to conduct later in 2011.

w w w . m e d i c a g o . c o m

MEDICAG0 USA

Exciting, Emerging Vaccine Technologies



Shortages of wheat and other food staples caused riots in developing countries in 2007 and 2008, while rising commodity prices contribute to recent political upheavals. Natural disasters and a ballooning worldwide population will only increase the strain on global food supplies.

Agriculture boosted by biotechnology can provide sustain-able solutions. Gwyn Riddick, vice president of agricultural biotechnology for the North Carolina Biotechnology Center, knows that many of these solutions will originate in North Carolina.

BOUNTIFUL AGRICULTURE ASSETS The state’s market leadership in agricultural products begins

with Christmas trees and other timber products, and extends into sweet potatoes, hogs, poultry, tobacco, cotton, peanuts, watermelons and herbs. Agriculture is the oldest and largest industry in North Carolina, generating upwards of $74 billion in revenue per year and employing more than 700,000 people. North Carolina in 2009 was eleventh in agricultural exports, according to the US Department of Agriculture, with $2.9 billion in exports.

Statistics from the National Center for Food and Agricultural Policy show that biotech crops add a total net value of more than $82 million to the state’s agricultural crops. The naturally occurring protein, bacteria Bacillus thuringiensis, in Bt cotton, which gives the plants resistance to some pests, is one example of how value is added to biotech crops.

“Bt cotton and Roundup-ReadyTM cotton have allowed North Carolina farmers to plant cotton again because they can manage the insects and weeds,” Riddick said. “People know that we’ve lost jobs in traditional industries like furniture and textiles, but this is an example of how biotech is helping traditional industries thrive and grow.”

Management of insects and weeds translates to increased yields and decreased use of pesticides. The National Center for Food and Agricultural Policy confi rms that with the adoption of biotech crops, pesticide usage in North Carolina was decreased by more than 3.5 million pounds of active ingredients in 2006, and food and fi ber production was boosted by 86 million pounds.

North Carolina is advancing even more agbiotech benefi ts. At NC A&T State University in Greensboro, scientist Mohamed Ahmedna, PhD, developed a process to make allergen-free peanuts. At the NC Research Campus in Kannapolis, eight universities have laboratories focused on researching agriculture, nutrition and links to preventing and treating disease. The state also boasts 18 agricultural research stations as well as tissue culture and micropropagation facilities.

The Biofuels Center of NC is leading the state’s burgeoning biofuels industry, beginning with the research and development of 13 feedstocks ranging from algae to switchgrass. With the NC Department of Agriculture and NC State University, feedstocks and fast-growth trees are in fi eld trials. The agronomic data will guarantee renewable biomass for biofuels production. The Biofuels Center offers grants to biofuels companies and sponsors statewide biofuels education.

AGBIOTECH CORPORATE CLUSTERMore than 4,000 people work in more than 70 agbiotech

fi rms, which include global leaders like BASF Plant Science, Bayer CropScience and Syngenta. AgBiotech businesses also include Avoca, Inc., the world’s leading processor of clary sage, from which they extract a key ingredient for the fragrance industry. Avoca contracts a total of 9,000 acres with a network of farmers in northeastern North Carolina.

Headquartered in Quebec, Canada, Medicago, Inc. is building a $42 million manufacturing facility in Research Triangle Park. The North Carolina facility will employ 85 people to manufacture a vaccine against H5N1 Avian Infl uenza. The vaccine will use virus-like particles grown in the cells of tobacco leaves.

Start-up Agile Sciences, founded by NC State University professors, is using organic compounds originally derived from sea sponges to disperse colonies of bacteria called biofi lms. Dispersion of these biofi lms could prevent millions of dollars in annual crops loss. SoyMeds, Inc., a spin-out of UNC Charlotte, is developing the use of soybeans as a platform technology for the expression of protein-based pharmaceuticals.

w w w . n c b i o t e c h . o r g / a g b i o


Boosting Agriculture with Biotech

NC AGRICULTURAL BIOTECHNOLOGY INITIATIVE To maximize the state’s strengths in agriculture and

biotechnology, the NC Biotechnology Center in partnership with an advisory council of 24 business, government and academic leaders launched the Agricultural Biotechnology Initiative. Their goal: increasing value of the state’s ag economy by $30 billion in 10 years. Riddick and his team, AgBiotech Innovation Manager Amber Niebauer and Biotechnology Crops Development Director Amber Shirley, PhD, foster the numerous interfaces between agriculture and biotechnology in order to build up the state’s agbiotech infrastructure.

One of their fi rst steps was to build on the Center’s undergraduate research fellowship program, Niebauer said. The program initially awarded 15 scholarships to college and university students across the state. Now in its third year, the expanded program will include two additional agbiotech fellowships, sponsored by Cotton Incorporated, and will continue to award scholarships to undergraduates conducting promising agbiotech research.

A survey of the state’s young entrepreneurial agbiotech companies has resulted in a comprehensive portfolio listing each company’s technologies and growth plans. The portfolio, Riddick said, helps the agbiotech team match companies with resources to grow more jobs and attract more agbiotech technologies and companies to the state.

Shirley is heading up the effort to create a greenhouse technology accelerator, a multi-user greenhouse facility that will combine several entrepreneurial companies in one leased space. “For technology to be commercialized, you have to have access to quality research greenhouse space,” Shirley said. “This facility will be something unique and differentiating for North Carolina internationally.” (See the NC Pavilion for the latest details.)

Shirley is also organizing a series of regional programs supported by the Golden LEAF Foundation, the NC State Extension Service,

the NC Department of Agriculture and other state partners that bring farmers and companies together to understand the opportunities that agbiotech opens up for new crops, new technologies and new ventures that will create a positive economic impact on the farm as well as benefi t consumers. The second program in the series focuses on the entrepreneurial farmer and the fi nancial, business and partnering skills needed to embrace biotech-related changes to the industry.

“Farmers will have to know how to track crops from seeds to the consumer,” Riddick said. Shirley added, “Growers are looking at how to get the value-added elements out of crops, like new specialty oils from soybeans or dye from industrial sweet potatoes. A farmer who grows soybeans with healthier oils captures what the public wants. It’s a different way of thinking so farmers need to prepare with new training.”

Riddick is confi dent that “30 in 10” will be achieved. “The NC Biotechnology Center has a tried-and-true approach to developing biotechnology in North Carolina that has worked for 27 years. We’re now applying it to agbiotech with growing success.”

w w w . n c b i o t e c h . o r g / a g b i o


“The NC Biotechnology Center has a tried and true approach to developing

biotechnology in North Carolina that has worked for 27 years. We’re now applying

it to agbiotech with growing success.”

- Gwynn Riddick, NC Biotechnology Center vice president of agricultural biotechnology


Here’s a fact. There are over seven billion people living on Earth today. By 2025, that number is projected to be over eight billion. This rapid population growth is expected to occur largely in developing countries, where food shortages and long-term food security issues are already a problem. The United Nations predicts that the number of hungry people will continue to rise dramatically, while the amount of arable land available to produce food, feed and fi ber crops will shrink.

Of the approximately 32 billion acres of land covering the Earth’s surface only about 4 billion acres are used for agriculture with another 8.5 billion acres used for meadowland and pasture. Demand is rising for food, animal feed and plants to produce biofuels. The effects of climate change and desertifi cation are other complicating factors, as well as the changing dietary habits of developing countries.

A leading force for innovation in the agricultural sector, Bayer CropScience is working to improve the world’s food security outlook by developing solutions to help increase crop yields by utilizing state-of-the-art technologies from classical chemistry to develop new plant traits and high-quality, high-performance seed. As the partner of choice for farmers worldwide, Bayer CropScience offers sustainable solutions from seed all the way through harvest.

RESPONDING TO THE NEEDS OF GROWERSModern plant breeding is becoming increasingly important

for global agriculture. That’s why the company has intensifi ed its focus on expanding its seeds and traits enterprise. “Bayer CropScience is committed to the development of tools to enhance growers’ ability to help meet the demands of global needs,” said North American CEO of Bayer CropScience LP Bill Bucker.

The company has a global presence in this arena, with seed businesses in four core crops – canola, cotton, rice and vegetables; signifi cant trait offerings for crops such as corn and soybeans; and an expanding focus on additional crops including wheat. With more than 1,500 researchers and breeders working on 60 plus research projects worldwide, the company is determined to bring to market game-changing seed and trait innovations in the areas of yield enhancement, stress tolerance and quality characteristics which are of particular interest to downstream users and consumers.

One example of the company’s research is its work to make plants more resistant to environmental stresses such as severe heat, cold or drought. Its goal is to enable plants to produce high, stable yields over the long-term in spite of changing environmental conditions; thereby, contributing to increasing global productivity.

To bring about these innovations, Bayer CropScience is tapping a full spectrum of techniques and technologies including classical breeding and the development of high-yielding hybrids. The company is also using genetic modifi cation to bring about further innovations not possible using conventional means alone.

COMMITTED TO SUSTAINABILITYAs Bayer CropScience contributes to meeting the needs

of an ever-growing and more-demanding world population, the company is making constant efforts to ensure that its new products and technologies can improve both the quantity and quality of food, feed and fi ber in a sustainable manner. By continually discovering new approaches to deliver such solutions, Bayer CropScience is helping to shape the future of agriculture and create value for its customers and society.

w w w . b a y e r c r o p s c i e n c e . c o m

BAYER CROPSCIENCE

A Global Leader in Agriculture




Ensuring a safe and nutritious food supply for a growing world population is a top priority for agriculture. Meeting these increasing demands via sustainable agriculture is an intense challenge. The solution is not to use more land, water or fertilizer. It is to fi nd innovations that create more effi cient ways to farm on the land already in use.

Agricultural biotechnology is providing solutions that increase crop yields; preserve and improve soils; enhance the control of pests, weeds and diseases; and produce healthier food with enhanced vitamin and nutrient levels.

BASF Plant Science is one of the world’s leading comp-anies providing innovative plant biotechnology solutions for agriculture. Today, about 700 employees are helping farmers meet the growing demand for improved agricultural productivity and healthier nutrition for humans and animals. BASF Plant Science’s unparalleled gene discovery platform focuses on yield and quality traits in crops such as corn, soybeans, wheat and rice.

BASF Plant Science is working with leading partners in the seed industry to commercialize its products.

Yield is the most important research and development priority at BASF Plant Science. Since 2007, BASF Plant Science and Monsanto have collaborated to improve yield in corn, soybeans, cotton, wheat and canola. BASF Plant Science recently furthered its commitment to rice research, the world’s largest food crop, by collaborating with Bayer CropScience to develop higher-yielding rice. This newest collaboration encompasses all major rice-growing geographies, with fi rst products expected by 2020.

Other partnerships focus on sugarbeets and sugarcane. In addition, BASF Plant Science is researching projects relating to nutritionally-enhanced corn for animal feed and higher content of Omega-3 fatty acids in oil crops for preventing cardiovascular diseases.

With its partners, BASF Plant Science is discovering real, tangible solutions to help solve the world’s growing food problem.

w w w . b a s f . c o m / p l a n t s c i e n c e

BASF PLANT SCIENCE

Approaching AgriculturalChallenges with Biotechnology Innovations


Those in the fi eld of cancer research and products should know this number: 132.

It’s the number of life science companies, university research centers and support companies North Carolina has focused on cancer research.

In North Carolina, researchers, physicians and state leaders are spearheading the fi ght against cancer. North Carolina is already directing immense resources and talent toward cancer research and treatment, extending from basic research to new treatments in clinical trials.

Those researchers brought in $195.5 million in National Institutes of Health funding for cancer research in 2009. The state’s researchers ranked thirteenth in American Cancer Society grants with $3.2 million in 2009.

COMMITTED TO CANCER RESEARCH Even the NC General Assembly is dedicated to reducing the

incidence of cancer, which is the number-one killer of adults in North Carolina. To fi ght this trend, North Carolina’s state legislature established The University Cancer Research Fund in 2007 with $25 million. The fund, at $50 million annually, underwrote the cost of the NC Cancer Hospital, the state’s only public cancer hospital. The 315,000-square-foot facility opened in 2009, tripling previous patient care space.

RESEARCH CENTERS AND HOSPITALSNC Cancer Hospital is the clinical home of the UNC

Lineberger Comprehensive Cancer Center in Chapel Hill. UNC Lineberger is one of only 40 centers in the country to receive the designation by the National Cancer Institute. Two other hospitals – the Comprehensive Cancer Center of Wake

Forest University in Winston-Salem and Duke Comprehensive Cancer Center in Durham – have also received the designation. These three comprehensive cancer centers were ranked among the top 50 cancer hospitals in the country, according to US News & World Report’s America’s Best Hospitals survey, 2010-2011.

Duke and UNC are two of the 55 medical research institutions funded by the NIH Clinical and Translational Science Awards (CTSA). They were awarded 2010 LIVESTRONG Community Impact Project awards. Wake Forest University Baptist Medical Center and the Leo Jenkins Cancer Center in Greenville were also 2010 LIVESTRONG winners.

The Jenkins Cancer Center, which is a part of East Carolina University, is another of the state’s cancer-fi ghting resources. More than eight percent of its patients take part in clinical trials. The hospital has 20 board-certifi ed physicians and surgeons with expertise in gynecological, pediatric and radiation oncology and breast, thoracic, gastrointestinal and endocrine cancers.

During the last 50 years, cancer research, treatment, patient care and prevention have made some cancers curable. According to the American Cancer Society, the death rate from cancer in the US decreased by 17 percent between 1991 and 2007. This is good news not only for cancer patients, survivors and their families, but also for the millions of people worldwide who will be diagnosed with cancer in the next year alone.

With companies, physicians, funding, comprehensive cancer centers, clinical trials and statewide support, the even better news is that North Carolina is dedicated to continue its leading role in the fi ght against cancer worldwide.

w w w . n c b i o t e c h . o r g / c a n c e r


Leading Cancer Research and Treatment

With companies, physicians, funding, comprehensive cancer centers, clinical trials and statewide support,

North Carolina furthers its leading role in the fi ght against cancer worldwide.


UNC Lineberger Comprehensive Cancer CenterDesignated a comprehensive cancer center in 1975, UNC Lineberger/NC

Cancer Hospital physicians handle more than 100,000 patient visits each year

and offer more than 160 clinical trials of the latest treatments developed at

UNC or available through affi liations with national clinical trials groups. UNC

Lineberger/NC Cancer Hospital’s staff of 1,120 includes 294 scientists from

more than 25 departments across the University of North Carolina at Chapel

Hill. The faculty holds $160 million (direct costs) in external grant funding.

UNC-CH was selected as one of 12 centers nationwide to participate in a

collaborative effort to characterize genomic changes that occur in cancer.

The National Cancer Institute awarded one of two national Comprehensive

Minority Institution Cancer Center Partnership Grants to UNC Lineberger

in partnership with NC Central University. With more than $7 million over

fi ve years, this is the largest sponsored research grant in NCCU history. UNC

Lineberger receives almost $4.9 million. NCI awarded $13.6 million in a fi ve-

year grant to the Carolina Center of Cancer Nanotechnology Excellence, based

at Lineberger. The CCCNE was launched in 2005 as part of NCI’s Alliance for

Nanotechnology in Cancer. This grant continues that support.

Comprehensive Cancer Center of Wake Forest University Designated a comprehensive cancer center in 1974, WFU enrolls more

than 1,000 patients per year in at least one of nearly 300 research studies

conducted by WFU researchers or their collaborators nationwide. WFU

recently won a $300,000 grant to improve clinical trials access for minority

populations. The Breast Care Center is one of only two centers in the state

and one of 27 nationally to be granted full accreditation by the National

Accreditation Program for Breast Centers (NAPBC), a program administered

by the American College of Surgeons. The other accredited center in North

Carolina is located in Greenville.

Duke Comprehensive Cancer CenterDesignated a comprehensive cancer center in 1972, Duke Comprehensive

Cancer Center was one of the original eight cancer centers established by

the National Cancer Act. The formation of the Duke Cancer Institute was

announced in November 2010. The Duke Cancer Institute is a single entity

that will unite physicians, researchers and educators across Duke’s medical

center, medical school and health system to accelerate research and improve

its translation to the most advanced patient care. The total investment in

the Duke Cancer Institute, including a new cancer center facility, will be

approximately $400 million.

More than 300 researchers and physicians and 500 clinical staff saw more

than 50,000 individuals with cancer last year. The Duke Comprehensive Cancer

Center has more than 500 clinical trials open for cancer patients, with clinical

and research partnerships in India, China and Singapore and across the United

States.

The cornerstone to North Carolina’s leadership in cancer research and treatment is the state’s three comprehensive cancer centers.

North Carolina’s Comprehensive Cancer Centers


Power of the Parks

Intellectual capital pulses from the labs of academia and industry and fl ows through the mountains into the agricultural fi elds and out into the oceans of North Carolina. Most of this intellectual capital is captured and advanced at the state’s seven research parks.

The power of these parks extends beyond physical locations where science happens to places and spaces where the newest treatments and products are developed. Networks of academic, industry and government researchers and business professionals utilize the combined resources of the parks to bring discoveries to market.

RESEARCH TRIANGLE PARKOne of the world’s fi rst and most well-recognized life science

business parks, Research Triangle Park is located in Raleigh-Durham and forms the foundation of the state’s life science industry. Research Triangle Park is home to more blue chip, international companies than any other science park in the world. Notable tenants include GlaxoSmithKline, IBM, Talecris, Biogen Idec, Bayer Crop Science, RTI International, Credit Suisse, Cisco and United Therapeutics.

CENTENNIAL CAMPUS Also in Raleigh, NC State University’s Centennial Campus

combines academic, corporate and government institutions to foster innovation and research. Centennial Campus is home to NC State’s colleges of textiles, engineering and, on the BioMedical Campus, veterinary medicine. Centennial has a diverse mix of over 60 tenants ranging from Red Hat, Talecris Biotherapeutics and the USDA Eastern Regional Offi ce to the Golden LEAF Biomanufacturing Training and Education Center (BTEC).

CAROLINA NORTH The newest research park is Carolina North, a research and

mixed-use academic campus under development two miles north of the main campus of UNC-Chapel Hill. Planned scientifi c specialties are biopharmaceutical research, nanotechnology, advanced materials, biomedical engineering, medical devices, imaging information technology and high-performance computing.

PIEDMONT TRIAD RESEARCH PARK Piedmont Triad Research Park is an urban campus located

in downtown Winston-Salem. PTRP is the home of the Wake Forest Institute for Regenerative Medicine and 56 companies with diverse foci including biomedical research, medical devices, nanotechnology, neuroscience and information technology. The NC Biotechnology Center’s Piedmont Triad Regional Offi ce is located at PTRP to coordinate access to the state’s biotech resources.

GATEWAY UNIVERSITY RESEARCH PARK Gateway University Park in Greensboro is a two-campus

collaboration between NC A&T State University and UNC Greensboro. The North Campus is a 75-acre campus with eight business and research enterprises. South Campus is another 75-acre campus where the USDA’s Natural Resource Conservation Service and the Joint School of Nanoscienece and Nanoengineering, another shared project of NC A&T State University and UNC Greensboro, are located.

NORTH CAROLINA RESEARCH CAMPUS The eight universities, community college and numerous

companies at the NC Research Campus in Kannapolis, north of Charlotte, are advancing the understanding of nutrition, agriculture and human health and the links to diseases like cancer, obesity and diabetes. The David H. Murdock Research Institute (DHMRI) is a central part of the campus’ discovery capabilities with next-generation sequencing, cutting-edge confocal imaging and the world’s fi rst actively shielded 950 MHz NMR.

CHARLOTTE RESEARCH INSTITUTE The Charlotte Research Institute, part of UNC Charlotte

and the NC Research Campus, has a range of scientifi c foci that include engineering, nanotechnology, computing, informatics, and chemistry that are investigated through Precision Metrology, eBusiness Technology and Bioinformatics research centers. CRI spurs business-university partnerships and UNC Charlotte spin-off companies. At the NC Research Campus, CRI operates the BioInformatics Service Center, where specialized computer systems and software, data management solutions and analysis further the work of the NC Research Campus’ university and business tenants.



Research Triangle Parkwww.rtp.org

Charlotte Research Institutewww.charlotteresearchinstitute.com

NC Research Campuswww.ncresearchcampus.net

Gateway University Parkwww.gatewayurp.com

Piedmont Triad Research Parkwww.ptrp.com

Carolina Northhttp://cn.unc.edu

Centennial Campushttp://centennial.ncsu.edu

The University of North Carolina (UNC), a multi-campus public university, is a leader in the research, development and application of new biotechnologies. UNC’s seventeen constituent universities are conducting both basic and applied research in a variety of biotech focus areas, working to train the next generation of scientists and engineers and streamlining processes by which the University partners with industries to commercialize biotech innovations.

UNC institutions across North Carolina are conducting cutting-edge biotechnology research with important implications for human health, energy use and sustainability and assistive technologies. In the most recent fi scal year, these institutions were awarded more than $661 million to conduct research in agricultural sciences, biology and biological sciences and health and clinical sciences. This level of funding for life sciences research represents 48 percent of the nearly $1.4 billion awarded to UNC institutions in that year.

The array of biotechnology research and training taking place at UNC institutions demonstrates why North Carolina is a leading state in the industry. At UNC Charlotte, bioinformatics researchers stay at the forefront of computational challenges in biology and biomedicine. UNC Chapel Hill’s Lineberger Cancer Center, with more than 290 researchers, is focused on

patient-specifi c cancer detection protocols and other strategies in personalized medicine. At East Carolina University, researchers are developing vaccines for multiple sclerosis, monkeypox and SARS.

With a $15 million award from the National Institute of Standards and Technology, UNC Wilmington and MARBIONC, the campus’ marine biotechnology center, are poised to lead the nation in translating discoveries about marine organisms into products and cures. Scientists from North Carolina A&T’s Engineering Research Center are developing next-generation biosensors and bioimplants. On NC State University’s acclaimed Centennial Campus, corporate and university partners share resources for second-generation DNA sequencing, antibody purifi cation and translational research.

The NC Research Campus, located in Kannapolis, is an innovative public-private research venture where seven UNC institutions are collaboratively conducting research projects related to nutrition and human health. UNC Greensboro is leading the effort on bioactive food compounds while UNC Chapel Hill scientists are examining the effect of personal biometrics on health outcomes. NC State University is enhancing the health benefi ts of food crops, and Appalachian State University is focused on human performance and nutritional

THE UNIVERSITY OF NORTH CAROLINA

Leading the State in Biotechnology Discovery and Translation

The David H. Murdock Research Institute’s Core Laboratory at the North Carolina Research Campus in Kannapolis, which houses one of the largest and most advanced scientifi c equipment collections in the world. Here, universities and private businesses test, explore and advance scientifi c knowledge across a variety of disciplines.

University of North Carolina continued on page 21




The NC Research Campus is emerging as a leading biotechnology hub for the study and advancement of health, nutrition and agriculture. In only fi ve years, the campus has achieved major milestones in funding, business development, workforce training and jobs.

Located in the Charlotte-metro region, the 350-acre campus hosts laboratories from NC State University, UNC Chapel Hill, UNC Greensboro, UNC Charlotte, NC Central University, Appalachian State University, NC A&T State University and Duke University. Together, scientists at the NC Research Campus have attracted $26 million in research funding. The 60 grants and outside contracts are funded primarily by the National Institutes of Health and the US Department of Agriculture. More than $22 million in additional applications are pending.

Duke University is conducting its groundbreaking MURDOCK Study. The biological samples of 5,000 partic-ipants are banked to foster the matching of medical histories, demographics and other variables to better understand heart disease, diabetes, arthritis, Alzheimer’s, multiple sclerosis and other diseases.

The universities are joined on campus by several businesses. General Mills, the sixth largest food company, and Monsanto, a leading, global agricultural company, joined the NC Research Campus in 2010. In laboratory space in the David H. Murdock Research Institute, the campus’ core laboratory, General Mills is researching vegetables and oats, and Monsanto enhanced nutrition and taste components in vegetables.

The 130 fulltime employees of the campus’ universities and businesses are augmented by on-site workforce training. Rowan-Cabarrus Community College’s 62,000-square-foot facility features state-of-the-art laboratories and chemistry and biology classrooms where students are working toward associate degrees in biotechnology.

Business, universities, the community college, employees and students are the synergy that is propelling the NC Research Campus forward as an emerging, thriving and leading center for biotechnology.

w w w . n c r e s e a r c h c a m p u s . n e t

NC RESEARCH CAMPUS

Emerging, Thriving, Leading

supplements. Industry tenants co-located at the NCRC include Dole Foods, General Mills and Monsanto.

In addition to a wide variety of research programs, the Univer-sity of North Carolina is also home to a number of world-class, biotechnology-based academic and training programs. The UNC/NCSU Joint Department of Biomedical Engineering continues to train the next generation of researchers in rehabilitation engineering, biomedical imaging and microsystems engineering. The Joint School of Nanoscience and Nanoengineering (NC A&T State/ UNC Greensboro) enrolled its fi rst class of graduate students in August 2010 and will open its new facility at the end of this year.

The University of North Carolina is dedicated to fostering long-lasting, productive collaborations with industry partners. In 2010, UNC institutions completed the fi rst phase of a compre-hensive Innovation Development and Transfer Initiative. The purpose of this initiative is to position UNC institutions as the “go-to” universities for partnering in innovation and increasing the impact of academic innovations in biotechnology for the benefi t of all.

w w w . n o r t h c a r o l i n a . e d u / r e s e a r c h

University of North Carolina continued on page 20

Employees of the universities and businesses at the NC Research Campus in Kannapolis, where nutrition, agriculture, biotechnology and health intersect.


In the small community of Four Oaks in Johnston County, July 19, 2010 was a landmark day. In a packed cafetorium at Four Oaks Elementary School, Governor Bev Perdue announced that BD (Becton, Dickinson and Company) was committing to create 187 new jobs and invest $38.4 million to build a warehouse and East Coast distribution center. With that announcement, Four Oaks had its new largest employer.

While BD and the biotech jobs it brought were new to Four Oaks, the company and the industry were not new to North Carolina. The state continues to have a stronghold as the number three biotechnology state in America.

“This success reinforces North Carolina’s stature as a top location for biotechnology companies – a reputation that we have worked hard to earn,” said Gov. Perdue

THE BIOTECH REPNorth Carolina started building a reputation as a front-runner

in biotech almost 30 years ago when leaders invested in the fi rst state-supported biotechnology center. In those 30 years, North Carolina has invested more than $200 million in biotechnology infrastructure, and the returns are enough to make Wall Street tycoons do a double-take.

In all there are more than 59,000 direct jobs at 539 biotech companies in North Carolina. The biotech presence in our state results in nearly $65 billion in economic activity – and the sector continues to show great promise.

“Biotechnology and life sciences are critical economic engines for North Carolina as we continue to build a diverse and thriving economy,” said Commerce Secretary Keith Crisco. “We have always been a state of innovation—so North Carolina is a perfect fi t as businesses look to create and expand their operations.”

JOBS, JOBS, JOBSIn fact, 2010 ended as it began for Governor Perdue and

Secretary Crisco, announcing new biotechnology jobs. A half-dozen announcements during the year resulted in a commitment to create more than 1,000 new jobs and invest $300 million in our communities. Here’s what those companies said about North Carolina:

“North Carolina’s quality of workforce, its training programs and overall understanding of biotech development models were critical factors in our decision to locate to RTP,” said Andy Sheldon, president and CEO of Medicago. Medicago announced it will create 85 jobs and invest more than $32 million dollars in North Carolina.

“We chose the Holly Springs location for this important project because of the great talent pool to recruit from, proximity to area universities and the relationship we have with our neighbors in the state, county and town of Holly Springs,” said Matthew Stober, global head of technical operations for Novartis Vaccines and Diagnostics.

“Establishing our new distribution center in Johnston County will enable BD to reduce cycle times and enhance the operational effectiveness of our entire supply chain. Additional benefi ts include the skilled workforce, transportation infrastructure and supportive government offi cials in the region,” said Stephen Sichak, BD senior vice president, integrated supply chain.

NORTH CAROLINA DEPARTMENT OF COMMERCE

A State of Innovation and Investment Biotechnology and Life Sciences Thrive in North Carolina




“The decision in 2000 to locate the US production facility in Monroe has been reinforced by the support received from local and state agencies as well as the caliber of team members added over the years,” said Rick McInnis, vice president of fi nance for Greiner Bio-One North America which announced an expansion of 51 jobs and investment of $25 million last year.

“This expansion project continues our productive relationship with the state of North Carolina and exemplifi es our commitment to serving the needs of people with diabetes,” said Doug Wallis, corporate vice president and general manager, Novo Nordisk Pharmaceutical Industries. Novo Nordisk partnered with Nypro in a plan to create 241 new jobs with a combined investment of $160 million.

“LabCorp has historically made major investments in the Piedmont Triad Region, including the construction of our new corporate headquarters in Burlington, and now creation of jobs in our new national billing operation in Greensboro,” said David P. King, chairman and chief executive offi cer of LabCorp. LabCorp announced plans to create 346 jobs and invest $4 million in February of last year.

COLLABORATIONSNorth Carolina benefi ts from close collaboration among

members of the state’s economic development team, including the NC Departments of Commerce and Transportation; the NC Community Colleges; local and regional governments; economic development agencies and workforce boards; the Employment Security Commission; utilities, railroads and the state ports; the University of North Carolina System; and private universities. Nonprofi ts such as the NC Center for Rural Economic Develop-ment and NC Golden LEAF play a critical role, as does the NC Biotechnology Center.

SECOND-TO-NONE WORKFORCENorth Carolina has good reason to be proud of its biotech-

nology workforce, a direct result of the state’s investment in collaborative programs designed to maintain its competitive edge. Training initiatives like NCBioImpact and BioNetwork ensure that North Carolina has the workforce international corporations need at the ready.

North Carolina’s proud reputation reached the highest levels when President Obama visited Forsyth Tech Community College in 2010 and then recognized the school’s efforts in his State of the Union address this year.

The president recognized Kathy Proctor, who was seated next to the First Lady, for her determination in seeking her biotech degree. The laid-off furniture worker’s journey is representative of the vision of state leaders who have worked to make North Carolina a biotech state.

w w w . t h r i v e n c . c o m

US President Barack Obama recognized the success of North Carolina’s biotechnology industry and training programs during an historic visit in December 2010 to Forsyth Technical Community College in Winston-Salem.

In all there are more than 59,000 direct jobs at

539 biotech companies in North Carolina. The biotech

presence in our state results in nearly $65 billion in

economic activity – and the sector continues to

show great promise.


Take your besPinehurst Pu

25 Research Triangle Regional Partnership

24 Medicago

23 Bayer CropScience

22 Talecris

21 North Carolina Community College System

20 Shepherd Research

19 The Hamner Institutes of Health Sciences

18 Novartis

17 DSM

16 Coats + Bennett

15 Nagoya University / NuTech

14 Treyco

13 Smith Anderson

12 Syngenta

11 West Pharma

10 Hockmeyer Equipment

9 iBiotech

8 Triangle BioSystems

7 Targacept

6 Piedmont Triad Regional Partnership

5 AgBiotech Initiative

4 Womble Carlyle

3 Biogen Idec

2 Electricities

1 North Carolina Department of Commerce

N.C. MResearch

Receptio

North Carolina Pav

Scan youto win

18 17

2019

22

21

24

25

23

1615

1413

12 11

87

43

109

65

21

48


st shot on the utting Green

26 Biomanufacturing Training and Education Center

27 UNC General Administration

28 GlaxoSmithKline

29 North Carolina Research Campus

30 Bent Creek Institute

31 North Carolina’s Eastern Region

32 Center of Innovation in Nanobiotechnology

33 Kymanox

34 Scynexis

35 NCBioImpact

36 Jenkins, Wilson, Taylor & Hunt

37 BioTechLogic

38 SAS

39 PSNC Energy

40 Beaker.com

41 BASF Plant Science

42 Forma Life Science Marketing

43 Method Sense

44 MARBIONC

45 NCBIO

46 Yonkers Industries

47 North Carolina Biotechnology Center

48 BE+K

Market h Center

on Desk

vilion Sponsor Map

ur badge n a trip

3132

2930

27

28

26

333435

3637

38

4142

4546

3940

4344

47




Nowadays, going to work in a factory has a whole new meaning in North Carolina.

Our factories include the world’s greatest concentration of vaccine manufacturers. Many are the largest and/or most productive of their kind, saving and improving lives in every corner of the globe.

We can point to more than 50 companies manufacturing a wide range of medicines, medical devices, diagnostics and delivery systems; agricultural products ranging from newly adapted high-effi ciency seeds to rare plants multiplied for the marketplace through cell culture and unique modifi cation techniques; and enzymes for biofuels, poultry feed and a wide range of other applications.

Great work if you can get it. We know. We have it. And we’re on the hunt for more of it.

Today’s North Carolina is a center of biomanufacturing. We’re populated by highly skilled factory workers making life-science products that are making unprecedented contributions to the world’s health and well-being.

These sites are resounding 21st-century answers to North Carolina’s furniture, cigarette and textile declines. And because North Carolina led the world by staking its claim in the life

sciences as a long-term economic development priority in 1984, it’s revered as a model for other states struggling to adjust to changes in the global economy.

A NEW NORTH CAROLINAThis is a new North Carolina, retooled and re-invented to

thrive on the global partnerships that feed innovation and sustain growth. It’s a landscape of irony. Across the state, these massive new factories are tapping the power of tiny things: cells; microprocessors; nanoparticles.

It’s a testament to North Carolinians’ smart, resourceful and determined nature. Energized by the knowledge that re-invention is the mother of opportunity, Tar Heels have retrained and educated themselves, created amazing new companies and also welcomed industrial giants from around the world.

Bill Buckner, president and CEO of Bayer CropScience’s US subsidiary, Bayer CropScience LP, put it eloquently in breaking ground for one of several recent multi-million-dollar investments in North Carolina:

“Bayer CropScience has strong roots in North Carolina and a clear intention to expand the business here,” he said. “In addition to having one of the best-trained biotechnology workforces

NORTH CAROLINA BIOTECHNOLOGY CENTER

NC Re-Invents ‘Factory Jobs’



in the country, this region is also a center of agricultural and biotechnology innovation. So when we were looking to expand our innovation capacity, it made great business sense to do so in this area. We are excited about establishing our Research and Development Innovation Center here, and the opportunities it provides for our company and the region.”

MAKING CONNECTIONSSince the North Carolina Biotechnology Center was founded

by state leaders in 1984 as the world’s fi rst job creation engine of its kind, we’ve brought together partners to connect the dots in ways that have quietly and effi ciently revolutionized our state’s business climate.

North Carolina’s life science sector, third-largest in the nation, grew by 29.1 percent from 2001 to 2008 – nearly double the nation’s bioscience growth rate.

We now have more than 59,000 North Carolinians working at 539 life-science companies statewide. Approximately 20,000 of those people are in new-wave manufacturing jobs – biomanufacturing.

So, while many furniture and textile jobs have moved overseas, we’ve plugged those losses with the best in life-science

manufacturing – domestic and imported. Some of the best-known are noted below.

Many of those came for our workforce, and stayed for our quality of life.

Check us out, and you’ll fi nd North Carolina’s sum total of lifestyle and life-science manufacturers impressive.

w w w . n c b i o t e c h . o r g / j o i n u s

NCBioImpact provides a range of training for current and future professionals in the life sciences.

phot

o: B

TEC

/ N

C St

ate

Uni

vers

ity


The North Carolina Biotechnology Center is the oldest new-tech organization of its kind in the world.

Biotech was on the cusp of becoming a new industry in 1984 when Governor Jim Hunt and other state leaders established the North Carolina Biotechnology Center to capitalize on its economic promise.

The goal was to secure the future, as the traditional tobacco, textile and furniture markets eroded.

It worked!

A MAJOR BIOTECH STATEToday, North Carolina is among

the top-three states in bioscience employment. North Carolina’s biotech base is one of the fastest-growing among the major biotech states. North Carolina is the nation’s leading hub for contract research and testing companies and a world leader in vaccine research and manufacturing.

Battelle quantifi ed the value of North Carolina’s industry-530-plus companies with more than 59,000 employees. A total of 227,000 jobs overall are supported through biotechnology which contributes $64.6 billion a year to the economy. Over the last decade, the state has invested $1.2 billion in biotechnology research, workforce development, company support and incentives.

ON A MISSION The Biotechnology Center is on a

mission to provide long-term economic and societal benefi ts to North Carolina through support of biotechnology research, business, education and strategic policy statewide.

The NC General Assembly funds the Biotechnology Center as a private, non-profi t organization dedicated exclusively to biotechnology development. Headquartered in Research Triangle Park, the Biotechnology Center has regional offi ces in Asheville, Greater Charlotte, Winston-Salem, Greenville and Wilmington.

WHAT’S RIGHT FOR BUSINESS DEVELOPMENT The Biotechnology Center is not a site for laboratory

research or company incubation. North Carolina has numerous wet labs, seven research parks and other facilities for that.

The Biotechnology Center also has a professionally staffed library that offers free access to high-dollar, high-value market research reports and other services. The library is one of the many services offered to help create well-paying jobs in the life sciences. The Biotech Center also:

> Serves as the statewide hub of life-science commercialization

> Bootstraps companies and new business sectors with loans and other support

> Funds key faculty recruitment and commercially promising research

> Links academic, business, civic and policy leaders

> Supports workforce development activities

> Provides curriculum development and workshops for educators.

The support of the Biotechnology Center spans biotechnology companies’ needs to connect with academia, government and a host of other resources.

w w w . n c b i o t e c h . o r g / j o i n u s

North Carolina is among the top-three states in bioscience companies,

and one of the fastest-growing of the major biotech states.

NORTH CAROLINA BIOTECHNOLOGY CENTER

Making Connections That Make Biotechnology Grow


Research Triangle Park is the fi rst research park of its kind and, after 50 years, the largest in the world. The success of RTP is dependent on two factors- the synergies created in the park and the diverse life science industry in the surrounding Research Triangle Region.

In the 13-county Research Triangle Region, which encom-passes the urban and rural counties surrounding Raleigh, Durham and Chapel Hill, 11 active industry clusters create a concentration of life science expertise that generates a high-level of innovation that attracts major life science companies like Novozymes North America, Inc., the world’s largest producer of industrial enzymes, and Pfi zer (formerly Wyeth), a global leader in research-based pharmaceuticals. Three of the nation’s premiere tier-one research universities, the University of North Carolina at Chapel Hill, Duke University and North Carolina State University, along with federal laboratories and contract research companies, attract more than $2 billion annually in research and development. The region is home to the largest concentration of contract research companies in the world

The region, despite the economic recession, continues to experience signifi cant investment. The UK-based, medical device manufacturer Smith and Nephew chose Durham to headquarter its biological therapies and spine product busi-nesses. Multi-national pharmaceutical company, Novartis, opened a 430,000 square-foot fl u vaccine manufacturing plant in Holly Springs. Talecris Biotherapeutics, a global biotherapeutic and biotechnology company producing treatments for therapeutic areas including immunology, pulmonology and hemostatis, announced a $269 million expansion in Johnston County. Bayer CropScience BioScience business acquired RTP-based Athenix Corp. and invested $10.2 million to expand its Wake County facility.

Supporting the region’s industry clusters are the state’s biotechnology training programs. The region’s seven community colleges are part of BioNetwork, the NC Community Colleges’ training program for the biotechnology and pharmaceutical industries. They offer the BioWork certifi cate, a basic training program for entry-level process technicians in the bioprocess, pharmaceutical and chemical manufacturing industries. Further training is available at two specialized facilities, the Golden LEAF Biomanufacturing Training and Education Center (BTEC) and NC Central University’s BRITE, Biomanufacturing Research Institute and Technology Enterprise.

The region is also the headquarters for the state’s leading advocacy and industry support organizations, the NC Biotechnology Center, NCBIO and the Council for Entrepreneurial Development. The Research Triangle Region, says Debbie Lilly, vice president of client services for Research Triangle Regional Partnership, has even more advantages: a rich quality of life; diverse people, communities and lifestyles; and collaboration between business, government and academia.

“Everyone works together, everyone collaborates,” she said. “Companies come here because of that. The life science companies across the street from each other talk and collaborate on drug development and new products. You don’t fi nd that any other place.”

w w w . r e s e a r c h t r i a n g l e . o r g

RESEARCH TRIANGLE REGIONAL PARTNERSHIP

Concentrated Life Science Expertise, High-Level Innovation

“Everyone works together, everyone collaborates.

Companies come here because of that. The life

science companies across the street from each other

talk and collaborate on drug development and new

products. You don’t fi nd that any other place.”

– Debbie Lilly, Research Triangle Regional Partnership




The Research Triangle Region

NAICS Codes for Life Sciences based on Battelle Memorial Institute. Source: NCESC, 2nd Qtr. 2010.

Industry Clusters

Advanced Gaming and E-Learning

Advanced Medical Care

Agricultural Biotechnology

Analytical Instrumentation

Biological Agents/Infectious Diseases

Clean Green Technologies

Defense Technologies

Informatics

Nanoscale Technologies

Pervasive Computing

Pharmaceuticals

Companies

16 Basic Chemical Manufacturing (3251)

7 Agricultural Chemical Manufacturing (3253)

41 Pharmaceutical & Medicine Manufacturing (3254)

57 Electronic Instrument Manufacturing (3345)

83 Medical Equipment and Supplies Mfg (3391)

558 Engineering (54133)

84 Testing Laboratories (54138)

427 Scientifi c Research and Development Svc (5417

163 Medical and Diagnostic Laboratories (6215)

Employees

720 Basic Chemical Manufacturing (3251)

70 Agricultural Chemical Manufacturing (3253)

11,482 Pharmaceutical & Medicine Manufacturing (3254)

5,763 Electronic Instrument Manufacturing (3345)

2,353 Medical Equipment and Supplies Mfg (3391)

7,080 Engineering (54133)

1,867 Testing Laboratories (54138)

13,032 Scientifi c Research and Development Svc (5417)

1,313 Medical and Diagnostic Laboratories (6215)

By 2050, our planet will have an estimated two billion more people to feed, two times more food to produce and 30 percent less farmland per capita. These looming realities are generating tremendous interest in agricultural sustainability.

Syngenta believes that sustainability is an ongoing journey of continuous improvement that builds on current best management practices. Progress will be made through systems that combine leading technology with effective land management and broader benchmarks: Not just bushels per acre, but water and energy per bushel.

Producing higher yields on existing crop acreage helps to keep other acreage in native landscapes that support wildlife and ecosystem services such as clean air and pollination. Technology is a key enabler. In the past year, Syngenta has released three new technologies to the marketplace aimed at increasing effi ciency and growing more from less.

■ The Agrisure Viptera™ trait received full regulatory approval in 2010. This novel insect management tool for corn protects against one of the broadest ranges of harmful insect pests to date.

■ In July 2010, Syngenta launched Agrisure Artesian™ technology, the fi rst water-optimized technology for corn hybrids. Agrisure Artesian technology enables corn plants to use available moisture more effi ciently, resulting in higher yields on drought-stressed acres including dryland and limited-irrigation farms.

■ The Enogen™ corn amylase trait was approved in February 2011 and is the fi rst genetically modifi ed output trait in corn designed to help the ethanol industry become more effi cient, profi table and environmentally friendly. Enogen corn can substantially reduce the energy and water consumed and the carbon emissions associated with ethanol production.

Research Triangle Park is home to the global center of biotechnology research and development for Syngenta and has been in the heart of biotech research in RTP for more than a quarter century.

w w w . s y n g e n t a b i o t e c h . c o m

SYNGENTA

Offering Solutions for Sustainability in Agriculture



All the Right Ingredients:Emerging Technologies Rise in North Carolina

Like a savory soup recipe, North Carolina’s bioscience industry has the right mix of ingredients – strong, science-based companies, diverse natural resources and world-class researchers simmered in a broth of strategic investment. The result? The rise of emerging technologies and new industries that bubble up new solutions to global needs for fuel, food and medicine.

REGENERATIVE MEDICINE – FROM HEALING TO CURING

Leading this sci-fi fi eld is Dr. Anthony Atala, MD, at the Wake Forest Institute for Regenerative Medicine in Winston-Salem. Atala’s team is developing healing cell therapies and replacement tissues and organs for more than 30 areas of the body. These therapies do more than heal, they have the potential to cure disease. And North Carolina has the scientifi c muscle to make it a reality.

Regenerative medicine in North Carolina is not only successful in the lab. Winston-Salem’s Tengion is developing neo-tissues and neo-organs derived from patients’ own cells. Greenville’s Pioneer Surgical Technology develops products for tissue regeneration like a sterile, injectable biopolymer. Argos Therapeutics, a Duke University spinout, has therapies in development based on the biology of dendritic cells that turn the human immune system on and off.

LAND TO SEA – BIOFUELS AND MARINE BIO Scientists everywhere are bringing together agriculture,

forestry, research and biomanufacturing to yield biofuels. North Carolina adds another ingredient to that research with natural resources that extend to the depths of the oceans. These natural resources, with research and some investment from the state of North Carolina, are spawning new industries around

biofuels and marine biotechnology.

The state’s biofuels companies are using non-food feedstocks like algae, poultry fat, waste vegetable oil and woody biomass to produce biodiesel and other biofuels. Novozymes North America, in Franklinton, northeast of Raleigh, is developing enzymes that create higher yields of ethanol at lower costs and an enzymatic method of converting hardwood to biofuels. The state’s focus on renewable liquid fuels is led by the Biofuels Center of North Carolina, whose goal is to reduce dependence on imported oil and liquid fuels by increasing production from in-state, locally grown biomass.

The Biofuels Center, located in Oxford, has granted nearly $6 million so far to facilitate development of better fuelstocks. Partnerships with university researchers to study 11 types of biomass – from fast growing trees to energy grasses – is opening new markets for the production and sale of biofuels.

INNOVATION CENTRALThe focus on biofuels originated from work by the NC

Biotechnology Center, which makes connections across the state’s industry, government and academic partners to grow the life science industry in the state. The Biotech Center focuses strategic investments to accelerate innovation across a number


The Center of Innovation for Nanobiotechnology (COIN) is a non-profi t organization that promotes innovation and commercialization in nanobiotech and nanomedicine.

Build a community

Connect innovators with promising nanobio-technology

Grow nanobiotech infrastructure

Drive successful new product development

Increase the profi le of the nanobiotech sector

Our Goals

offi ce: (919)680-2070 | fax: (919)680-2906 | www.nc-coin.org

www.nc-coin.org

FOLLOW US ON THE NETAND GET

CONNECTED!


of other areas through its Centers of Innovation, which are IbilitiTM (advancing emerging medical technologies), drug discovery, nanobiotechnology and marine biotechnology.

The Center of Innovation in Marine Biotechnology is the coalition of business leaders and researchers at seven universities who are building on the state’s other pool of natural resources to commercialize marine discoveries in medicine, food, food safety and environmental testing.

UNC Wilmington’s MARBIONC, marine biotechnology in North Carolina, is leading the transfer of marine research into market-ready applications. Their drug discovery program is screening marine microbes to identify new sources for antibiotics. Brevenol, a toxin produced by Karenia brevis, or red tide, that blocks the activity of lung-irritating toxins, shows promise as a potential treatment for cystic fi brosis and other respiratory diseases. World Ocean Solutions works with UNC Wilmington’s Center for Marine Science and MARBIONC to manufacture and sell brevatoxins, okadaic acid, ELISA kits and other products. MARBIONC spin-off companies are developing aquaculture techniques in fi sh farming to improve the availability and quality of fi sh like fl ounder and black sea bass.

The investment in marine biotechnology is breeding other success. North Carolina is home to marine biotech companies like BioLume, in Wendell, with research and development in bioluminescent chemistry for food, beverage, cosmetic and diagnostic imaging markets.

NANOBIOTECHNOLOGY – NANOTECH MEETS MEDICINE

COIN is the Center of Innovation that stimulates entre-preneurship and commercialization across the state in nanobiotechnology. COIN starts from a position of strength - more than 40 companies specialize in nanobio drug discovery, drug delivery, advanced medical technology and nanotools. According to the Woodrow Wilson International Center Project on Emerging Nanotechnologies, North Carolina is eighth and the Raleigh area is fourth in the nation in nanobiotechnology.

In the last year, NanoMed Corp relocated from New Jersey to Winston-Salem, and UNC Chapel Hill spun out nanobiotech start-up Qualiber to develop and commercialize siRNA tech-nology. RTI International, one of the state’s renowned research institutions, was awarded a $2.9 million, three-year National Institutes of Health contract to establish a nanomaterials registry.

North Carolina is breaking new ground in nanobiotech education and training with the Joint School of Nanoscience and Nanoengineering, a program of UNC Greensboro and

NC A&T State University, and an associate degree in nanotechnology from Forsyth Technical Community College.

Thirty years ago when the state began building a biotech-nology sector, the science itself was an emerging technology. It now returns $64.6 billion annually to the state’s economy. Building on that successful model and long-established collaborations, North Carolina is investing in emerging technologies that benefi t the world with new solutions to fuel, feed and heal.

BIOMANUFACTURING TRAINING AND EDUCATION CENTER

Providing a Range of Services to the Biomanufacturing Industry and Enhancing Economic Development

The Golden LEAF Biomanufacturing Training and Education Center (BTEC) is a unique, cross-disciplinary instructional center that provides educational and training opportunities to develop skilled professionals for the biomanufacturing industry. It also supplies bioprocess and analytical services to a wide range of customers from industry and academia. BTEC, located on North Carolina State University’s Centennial Campus, is an 82,500-gross-square-foot center that features more than $12.5 million of industry-standard equipment, including labs with bench-, intermediate- and pilot-scale bioprocessing equipment and a simulated-cGMP pilot plant facility capable of producing biopharmaceutical products and packaging them in a sterile environment.

WORKFORCE DEVELOPMENTBTEC offers an array of open-enrollment short courses for

industry professionals, and participants receive continuing education units (CEUs) upon completion. Primary instructional tracks are:

1 > Biomanufacturing,

2 > Bioprocess development,

3 > Bioprocess engineering,

4 > Analytical technologies.

BTEC also provides customized training courses designed in collaboration with and delivered to local, national and international companies. Recent custom courses for corporate clients include Hands-on Biomanufacturing, Single-Use Disposables in Biomanufacturing, Downstream Biopharmaceutical Processes: Fundamentals and Design and Cleaning and Sanitization of Bioprocessing Equipment. BTEC also has ongoing programs with the US Food and Drug Administration (FDA) to provide biomanufacturing training to inspectors and with the Biomedical Advanced Research and Development Authority (BARDA) to deliver training in cGMP infl uenza vaccine manufacturing. In 2010 alone, more than 200 industry professionals attended BTEC’s various pro-fessional course offerings.

COLLABORATION WITH INDUSTRYBTEC’s Bioprocess and Analytical Services initiative

provides process development, technology development and analytical testing/method development services to companies with biomanufacturing interests and to academic institutions. In the past 18 months, BTEC has collaborated with corporate and academic clients on more than 10 major projects involving topics ranging from insect cell line development for interleukin production to scale-up of mammalian cell culture processes to pilot-scale range-fi nding studies for inclusion body recovery in an E. coli process.

ACADEMIC PROGRAMSFor undergraduates and graduate students, BTEC offers an array

of degree programs including an undergraduate biomanufacturing minor, an undergraduate certifi cate in biomanufacturing, a post-baccalaureate certifi cate in biomanufacturing and the fi rst graduate degrees in biomanufacturing in the United States. Funded by the National Science Foundation, BTEC’s Professional Science Masters (PSM) program offers a Master of Biomanufacturing (non-thesis) and a Master of Science in Biomanufacturing (thesis). More than 250 students enroll in BTEC courses each semester.

ECONOMIC DEVELOPMENTIn cooperation with our major partners in NCBioImpact,

the state’s industry education partnership, BTEC fosters economic growth in North Carolina. Our industry expertise, unique facilities, innovative curriculum and hands-on approach to education and training are helping to create a world-class biomanufacturing workforce. New industries considering relocating to the state and those already here can’t help but be impressed. We invite you to come see what BTEC has to offer!

w w w . b t e c . n c s u . e d u



Even with a bachelor’s degree in chemistry, Melvernia Holly found that securing a job required adding specifi c in-depth training to her resume. Through BioNetwork, the NC Community Colleges’ training program for the biotechnology, pharmaceutical and life science industry, Holly received a training scholarship to take two courses at the Pharmaceutical Center’s Analytical Training Center. Within a month, Holly was employed at a biotech company.

Success stories like Holly’s are commonplace at BioNetwork’s seven centers:

■ Capstone Center and Validation Academy hosted by Wake Technical Community College, Raleigh

■ Bioprocessing Center hosted by Pitt Community College, Greenville

■ Pharmaceutical Center hosted by Forsyth and Guilford Technical community colleges, Winston-Salem and Greensboro

■ National Center for the Biotechnology Workforce hosted by Forsyth Technical Community College, Winston-Salem

■ BioAgriculture Center hosted by Robeson Community College, Lumberton

■ BioEducation Center hosted by Gaston College, Dallas

■ BioBusiness Center hosted by Asheville-Buncombe Technical Community College, Asheville

Training at each center prepares new and incumbent workers for biotech jobs from entry-to management-level. Customized training programs and short and curriculum-designed courses. All courses meet industry training standards and can be delivered anywhere in North Carolina. Online training encompasses instructional videos, games, courses and BioForum, a free, monthly training webinar.

BioNetwork’s training supports the state’s 58 community colleges and their two-year, life science degrees, internships, job placement services and reciprocal agreements with the state’s universities that allow students to pursue four-year, life science degrees.

“Hands-on experience gave me the opportunity to bolster my resume,” Holly said, “and provided me with the skills that I would not have gained anywhere else.”

w w w . n c b i o n e t w o r k . o r g

NC COMMUNITY COLLEGE SYSTEM

One Step to a Biotech Career



NORTH CAROLINA COMMUNITY COLLEGES’ SPECIALIZED TRAINING FORCE FOR THE STATE’S BIOTECHNOLOGY, PHARMACEUTICAL AND LIFE SCIENCE INDUSTRY.

Our seven centers, strategically and geographically positioned across the state, develop short and curriculum designed courses to meet the needs of industry. The centers themselves are staffed with highly skilled industry trained experts that are constantly developing workforce training programs that can be delivered anywhere in North Carolina.

email: [email protected] or visit us at www.ncbionetwork.org

PIEDMONT TRIAD PARTNERSHIP

The Right Place for Life Science Companies

200 East First Street, Winston Salem, NC 27101

Building Health, Restoring IndependenceSM

www.targacept.com



The Piedmont Triad, a 12-county region surrounding Winston-Salem, High Point and Greensboro, is a thriving life science cluster. More than 200 life science companies anchored by leading corporations like LabCorp, Targacept, TransTech Pharma, Cook Medical and Banner Pharmacaps refl ect the diversity of the region’s six sub-clusters: biotechnology, nanotechnology, pharmaceuticals, regenerative medicine, research and medical device manufacturing.

The Wake Forest Institute for Regenerative Medicine is a global leader in engineered tissues for conditions ranging from congenital abnormalities to acquired pathologies such as infection, tumors, trauma and chronic diseases. The Piedmont Triad, through a regional consortium and a grant from the NC Biotechnology Center, is the state’s original home of the Center of Innovation in Nanobiotechnology.

The region boasts a 24 percent increase in life science companies due in part to the investment in two research parks.

Piedmont Triad Research Park is a master-planned urban park located in downtown Winston-Salem with more than 554,000 square feet of wet lab, offi ce, meeting and residential space. Gateway University Research Park is a two-campus park developed in collaboration with NC A&T State University and UNC Greensboro that, when fully developed, will generate an economic impact of $50 million per year.

The Piedmont Triad’s life science industry benefi ts from low operating costs, a central East Coast location and a qualifi ed workforce of over 5,400 skilled employees. The region offers nine community colleges and 11 four-year institutions, including doctorate-granting, research universities UNC Greensboro, NC A&T State University and Wake Forest University.

w w w . p i e d m o n t t r i a d n c . c o m



DSM is a global provider of fi nished dosage form manu-facturing and related services to the pharmaceutical and biopharmaceutical markets.

With a 1.5-million-square-foot facility on more than 640 acres in Greenville, DSM offers more than 40 years of experience in aseptic fi lling of liquid and lyophilized compounds and manufacture of tablets and capsules. In addition to commercial supply of traditional dosage forms, DSM specializes in fi lling of sterile cytotoxic compounds and production of clinical trial materials and controlled substances. DSM also offers a full range of pharmaceutical development services.

DSM’s Finished Dosage Form facility is approved by the FDA, EMEA and many other international regulatory agencies. This enables DSM to ship to countries throughout the world. DSM’s superior regulatory audit history is available upon request. The company has fi ve consecutive FDA inspections with no 483s

issued and more than 90 percent of pre-approval inspections waived since 2007. DSM also maintains Potent Compound Safety Certifi cation from SafeBridge Consultants, Inc. for handling of cytotoxic APIs and drug products.

DSM was ranked number one in 2009 and 2010 on the Dow Jones Sustainability Index. The company has a solid, independent fi nancial position with a Single A credit rating.

Corporate sustainability, a compelling facility, unparalleled experience, premium quality and regulatory excellence are factors that differentiate DSM as a business partner in bringing long-term total value to customers.

w w w . d s m p h a r m a c e u t i c a l s . c o m

DSM

Long-Term Total Value to Customers

WEST PHARMA

Resources for Biopharmaceutical Risk Mitigation

Risk mitigation strategies are a part of the biopharma-ceutical drug development process from the earliest stages. In the early stages, biopharmaceutical developers should consider the packaging components and systems that will contain and deliver the drug product throughout its life cycle. This process can identify solutions to potential risk factors, which can help the company meet Quality by Design initiatives and avoid costly delays caused by a container closure system that is incompatible with the drug product.

As the drug progresses to clinical trials, it is typically contained in a system consisting of a vial, stopper and seal. As an alternative to a trial-and-error selection process, biopharmaceutical companies can choose the West Ready Pack® system.

Ready Pack components are suitable for laboratory work and for small-quantity fi lling of high-value drugs. The components are compatible with one another and proven to assure container closure integrity. Ready Pack components are available quickly

and conveniently. Because the components are delivered ready to use, you can eliminate component preparation from your processing, saving time and money.

Derive even more value from the Ready Pack system by selecting Daikyo Crystal Zenith® vials and copolymer Flip-Off® seals, ideal for low-temperature storage and shipping. Crystal Zenith vials are suitable for storing high-value drug products. A Crystal Zenith solution can solve issues associated with glass systems, such as breakage and glass delamination.

A Daikyo Crystal Zenith® prefi llable syringe system is an ideal containment and delivery solution for high-value biopharmaceutical drugs. Crystal Zenith solutions help advance risk mitigation strategies because the drug is contained in the same material throughout its lifecycle.

w w w . w e s t p h a r m a . c o m

West is proud to support the biopharmaceutical industry from its facility in Kinston.

▲ Out-Licensing and In-licensing

▲ Mergers and Acquisitions

▲ Sales and Marketing

▲ Trade and Distribution

▲ Manufacturing and Clinical Development

A Global Business Partner

[email protected] » ibiotech.biz

Business Development with a Global Outreach





SCYNEXIS, Inc. is a drug discovery and development company located in Research Triangle Park that began as an Aventis spin-out company in 2000. SCYNEXIS has fully-integrated research and development capabilities which include medicinal chemistry, advanced biological screening, in vitro pharmacology and ADMET, DMPK, bioanalytical and analytical chemistry, process chemistry and cGMP manufacturing. Our teams are expert in moving projects from concept to clinic, with the help of powerful proprietary technologies including our HEOS® SaaS research collaboration platform and MEDCHEM-FACTORY®. SCYNEXIS has considerable expertise in a number of therapeutic areas and has been especially active in infectious diseases, animal health including parasitology, diseases of the central nervous system, oncology and ophthalmology. The expertise that has delivered eleven pre-clinical drug candidates over the last fi ve years, including SCYNEXIS’ anti-HCV cyclophilin inhibitor SCY-635, is available to pharmaceutical and biotechnology companies and global health organizations on a partnership basis.

SCYNEXIS has been involved in global health during its entire history and has contributed a number of innovations to the fi eld. These contributions include the discovery and optimization of the fi rst novel pre-clinical candidate compound for Human African Trypanosomiasis in thirty years this advancement came through SCYNEXIS’ participation in the DNDi-sponsored HAT project, in collaboration with Anacor Pharmaceuticals and Pace University. SCYNEXIS has also contributed to the advancement of research on neglected diseases via the HEOS® software platform, a SaaS application which has become the standard global health research collaboration software in use today.

SCYNEXIS has recently organized the SCYNEXIS Global Health Alliance through which it is offering its established expertise and technologies to life science organizations that are interested in participating in an effort to bring the best technology forward to address global health challenges.

w w w . s c y n e x i s . c o m

SCYNEXIS, INC.

From Concept To Clinic With Speed And Innovation



NC Pavilion Bronze Sponsors


(919) 313-3962 |

The Complete PackageELECTRICITIES

Proven, Comprehensive Economic Development Solutions

North Carolina’s Public Power communities are among the best places in the country to live and do business. ElectriCities’ experienced economic development group is dedicated to helping these communities continue to grow and prosper.

From site selection to marketing to targeted recruiting to grant assistance, and we have tools and expertise for all your economic development needs, every step of the way.

Public Power communities meet the needs of new and expanding business, contributing more than 13,000 new jobs and $2.2 billion to regional economies.

“NC Public Power communities are regional hubs of economic growth,” said Brenda Daniels, ElectriCities economic development manager. “Public Power communities offer excellent local customer service, innovative programs to provide highly reliable electricity and competitive industrial electric rates. These amenities combined with local, dedicated city staff meet the needs

of your biotech company and make NC Public Power communities the place for the growing biotech sector.”

The Prime Power Parks, two innovative projects that guarantee highly, reliable electricity are the state’s only industrial parks with on-site backup power generation. Tenants can protect their operations from power outages without the cost of their own redundant power systems.

Partnering with the NC Biotechnology Center and regional and local economic development organizations, ElectriCities Economic Development provides a one-stop source for site selection in North Carolina. Named one of the top three utility service providers in North Carolina by Southern Business and Development, ElectriCities provides the services that facilitate new and expanding industry.

North Carolina is the perfect climate for biotechnology, and NC Public Power communities are the ideal locations for biotechnology companies.

w w w . e l e c t r i c i t i e s . c o m

Visit www.trianglebiosystems.com for more information and specifi cationsTriangle BioSystems | 2224 Page Road, Suite 108 | Durham, NC 27703 | 919-361-2663

Everything You Need to Get Started Recording Neural Signals

Also, see our other “Total Solution Offerings”for Wireless, Multiplexing and Stimulation

“The Total Tethered Neural

Recording Solution”

■ T-Series 8 Channel, Gain 100 Tethered Headstage

■ T-Series DAQ Base Station

■ NeuroWare Neural Recording DAQ Software

■ Cables (Headstage – A/D, USB, Power)

■ 16 Channel and 32 Channel Tethered Systems Also Available

Price – $6,495.00 USD

*Electrodes Sold Separately

Data Acquisition with NeurowareTM

Headstage

DAQ Base Station

Triangle BioSystems is your total solution provider for neuro recording, stimulation and data acquisition hardware & software.

1400 Crescent Green Suite 300, Cary, North Carolina

tel: 919-854-1844 • fax: 919-854-2084 • (800) 575-1278

Coats + Bennett is a full service

intellectual property law fi rm

with extensive experience

across a range of technologies

and businesses. Our areas of

practice include patent and

other intellectual property

litigation, patent application preparation and

prosecution, copyrights, and trademarks.

connect + empower + protect

YONKERS INDUSTRIES

Thriving on Adaptability and Flexibility

When leading global biotech and pharmaceutical companies like Amgen, Biogen Idec, GlaxoSmithKline, Merck, Becton Dickenson and Pfi zer headline your client list, there must be a reason. Terry Costello, Yonkers Industries president and COO, names the company’s ability to remain adaptable and fl exible as a primary factor.

Yonkers builds, expands, renovates and modernizes pharmaceutical and biotechnology facilities in the US, Puerto Rico, Central and South America, Southeast Asia and Ireland. Even with the recession, the company continues to work with 15 to 20 clients at 25 to 30 sites in the US and Puerto Rico. As new facility construction declined over the last two years, Yonkers adapted, taking on more renovations and modernization of plants, which are the types of projects that launched the company nearly 28 years ago.

“Our clients have had to adapt,” Costello said. “So we’ve had to adapt to their spending patterns and their needs. We’ve also had to adapt to their desire to keep costs down.

We’ve had to become more effi cient and productive as a company in the way we mange and execute projects. We’ve had to help our clients reduce the cost of capital projects, keep our quality high and increase the value.”

Responding to clients has also meant growth in other service areas like maintenance management and commissioning/qualifi cation (IOQ). These groups, Costello explained, have experienced growth as clients outsource functions they once managed internally.

“I’ve always said as a contractor that we sometimes tend to think we’re going to dictate how our clients use us,” Costello said. “Historically, clients will ultimately decide how and when they will utilize you.”

It is this philosophy that keeps Yonkers and their clients agile and thriving in tough economic times and in an ever-changing and demanding pharmaceutical industry.

w w w . y o n k e r s i n d u s t r i e s . c o m

Shepherd Research

www.shepherdresearch.com [email protected]

“I am passionate about building relationships to bring excellent science to market. It’s all about scientifi c insights, business connections, and delivering results.”

– Nancy Shepherd, PhD MBA Founder and CEO

Strategic Thinking | Operational Excellence | Contractual Relationships

We help YOU GROW





Talecris Biotherapeutics, Inc. (TLCR) is a global company that discovers, develops and produces eleven critical-care treatments for people with rare, life-threatening conditions. Each Talecris therapy is derived from human plasma, a rich source of proteins that support healthy physical and neurologic function. Talecris extracts the vital proteins from plasma and transforms them into specialized therapies for patients whose diseases cannot be adequately treated with traditional pharmaceuticals. Therapies made from plasma are primarily used to replace or restore missing proteins among people with genetic diseases such as immune defi ciencies, blood disorders and genetic emphysema as well as other serious medical conditions. The company’s products reside in four therapeutic areas: immunology, pulmonology, neurology and hemostasis.

Founded in 2005, Talecris is built upon a 68-year legacy in the plasma protein industry that began in 1942, when its predecessor pioneered plasma fractionation and developed the fi rst blood product, Albumin. Today Talecris employs more

than 5,000 professionals worldwide. Areas of primary focus include research and development, pathogen safety, manufacturing and sales and marketing. Additionally, Talecris owns and operates 69 US plasma collection centers, known as Talecris Plasma Resources, where plasma is collected for use in manufacturing the company’s plasma-derived protein therapies.

Talecris’ corporate headquarters are located in the bio-technology hub of Research Triangle Park, NC USA with additional regional headquarters in Toronto, Canada and Frankfurt, Germany. The company’s primary manufacturing facility is located in Clayton, with additional fractionation capacity in Melville, NY.

w w w . t a l e c r i s . c o m

TALECRIS BIOTHERAPEUTICS, INC.

Hope for Patients With Rare, Life-Threatening Diseases


Build, Test, Market and Protect:NC Supports Biotech and Life Science Companies

Dennis Gillings and Fred Eshelman may not be household names, but they are the founding fathers of two global companies that launched the support sector – a longtime strength of North Carolina’s.

Gillings, PhD CBRE, is the founder, chairman and chief executive offi cer of Quintiles Transnational Corporation, one of the largest global providers of clinical trials and commercial marketing services to the pharmaceutical and biotechnology industries. With headquarters in Durham, Quintiles employs 22,000 people in 60 countries.

Eshelman, PharmD, is the executive chairman of PPD, Inc. Headquartered in Wilmington, PPD has locations in 44 countries providing drug discovery and development and life cycle management services to the pharmaceutical, biotechnology, medical device, academic and government sectors.

PPD and Quintiles represent the tip of the iceberg when it comes to CROs in North Carolina. The state boasts 121 companies that supply every stage of clinical trial support and every level of service from trial design to report submissions to ensure that drug and medical device discoveries gain approval and succeed in the US and worldwide.

North Carolina’s support of biotech companies goes beyond CROs. According to the NC Biotechnology Center’s online business directory, more than 1,000 companies provide direct support to biotech and life science fi rms and academic and government institutions.

Companies in North Carolina can build factories and plants; market and package products; provide software and IT

support; and clean and service equipment. The scope of support companies spans an even broader panorama of legal expertise in patents and intellectual property, accounting, fi nancial services and consulting expertise. Companies specialize in the sale and development of laboratory products and equipment while others staff offi ce, sales and research positions. Particular to North Carolina is the manufacturing and engineering base that produces specialized coatings, materials and textiles that play a crucial role in the development of cutting-edge discoveries in emerging technologies in the state.

North Carolina takes support a step further with three education and training programs – NC State University’s Golden LEAF Biomanufacturing Training and Education Center (BTEC), NC Central University’s Biomanufacturing Research Institute and Technology Enterprise (BRITE) and the NC Community Colleges’ BioNetwork. The three training partners come together under the umbrella of NCBioImpact, a consortium of state leaders and educational institutions, which coordinate training and education across the state.

Overall, North Carolina’s universities, start-up companies and established fi rms lead in the translation of research and development to marketable discoveries, in part, due to continued industry support at every stage of development. Most importantly, North Carolina has a history of success in biotechnology and life science that is backed up by long-standing government commitment that’s created a business climate that not just supports but provides the complete package for biotech and life science success.

Overall, North Carolina’s universities, start-up companies and established fi rms lead in the translation of

research and development to marketable discoveries, in part, due to continued industry support at every

stage of development.


>>>>>• Movement from “What is the FDA?”

to FDA compliance and successful partner audit in 3 months

• Movement from “What is a QMS?” to ISO 13485 certifi cation and CE mark in 4 months

• Validated Medical Device and Clinical Trial software in weeks instead of months

• Virtual RA & QA services enabling low overhead and high effectiveness

• FDA submission support

• Global Experience: US, Canada, EU, Pacifi c Rim

• GxP, 21 CFR Part 11, ISO 13485, HIPAA, CMM Expertise

• Strategic compliance and quality system development

• Process and validation strategies and execution for software and hardware

• Vendor and internal audits

• Software design control evaluations

• Risk assessment and remediation

Packaged Services

Customized Right-Sized RA/QA expertise delivering clear, practical commercialization paths.

Solutions for Life Science

>>>>> Recent Client Success Paths

North Carolina Life Sciences >The Complete PackageNC Pavilion Bronze SponsorsNC Supports Companies

North Carolina’s biotechnology and life science industry provides more than 227,000 jobs. Many of those are in the companies that provide support to the industry:

• Accounting

• Chemical and gas manufacturing and distribution

• Clinical research and data management services

• Coatings

• Communications and marketing

• Computer software and networking

• Construction

• Consulting (strategic, operational, business development, commercialization, licensing, process development and regulatory affairs, access to foreign markets and more.)

• Economic development organizations

• Education

• Engineering

• Equipment leasing

• Human Resources

• Janitorial

• Laboratory and plant equipment manufacturing and sales

• Law fi rms

• Materials manufacturing and sales

• Medical textile and industrial fabrics manufacturing

• Packaging

• Real estate

• Research supplies

• Sales support

• Staffi ng

• Testing laboratories

Whatever your company needs, North Carolina has a company that can provide it.

n c b i o t e c h . o r g / d i r e c t o r y (919) 313-3962 | www.MethodSense.com | [email protected]


Editorial Advisors:

Russ H. ReadExecutive DirectorNational Center for the Biotechnology Workforce

Nick MeachamCommunications CoordinatorBioNetwork

Patty BrownSr. Instructional DesignerBTEC-Biomanufacturing Training & Education CenterNC State University

Bill WelshAssociate Director Strategic ProgramsBTEC-Biomanufacturing Training & Education CenterNC State University

Advisory Board: Daniel G. Baden, PhDMARBIONCExecutive PrincipalDirector, Center for Marine Science

Marjorie Benbow, JD, MBA, MSPH Executive Director, Greater Charlotte Offi ce North Carolina Biotechnology Center

Barry Burks, PhDAssociate DirectorCharlotte Research InstituteUNC Charlotte

Yonnie Butler, MBAAssistant Director, Master of Managementin Clinical Informatics (MMCi)Health Sector Management (HSM)Duke University - The Fuqua School of Business

Steve Fontana, JD Senior Technology Development Offi cer MARBIONC

Sheetal Ghelani, PhDBusiness Development ManagerDavid H. Murdock Research Institute

Nancy JohnstonExecutive Director, Piedmont Triad Offi ceNorth Carolina Biotechnology Center

Linda Love Industrial Relations ManagerBiomanufacturing Research Institute and Technology Enterprise (BRITE)North Carolina Central University

Matthew MeyerAssociate Vice President Innovation and BiotechnologyNC Community College System

Jennifer Montague, PhDVice President Business Development BioCytics, Inc.

Impact is published in partnership with BioNetwork, a biotechnology and pharmaceutical training program of the NC Community College System and NC Central University’s BRITE, Biomanufacturing Research Institute and Training Enterprise.

impact coversthe business of science –

EARLY STAGE TECHNOLOGY. EMERGING RESEARCH. TRENDS AND ISSUES. WORKFORCE DEVELOPMENT.

from biotechnology, life sciences, healthcare and medical

devices to green technologies and sustainable energy.

www.readimpact.com or call 704-200-5070

impact is published in partnership with:

biotechnology and life sciencesadvancing the business of

BioNetwork The NC Community College System 919-807-7155 Matthew MeyerAssociate Vice PresidentInnovation and Biotechnology [email protected]

impact Sponsors

NC State University Golden LEAF Biomanufacturing Training and Education Center (BTEC)Patty BrownSr. Instructional DesignerCampus Box 7928, Raleigh, NC [email protected]://www.btec.ncsu.edu

NC Central University BRITELinda LoveIndustrial Relations [email protected]://brite.nccu.edu

PublisherCC Publish Inc.

EditorialJennifer Woodford, Editor/Senior [email protected]

Design Janell Henry, [email protected]

ProductionKathy Williams, [email protected]

Photography contributed by:BioNetworkBTECBCGKeraneticsMethodSenseTengion

impact biotech and life sciences magazine is published on recycled paper with soy-based inks. Postage paid at Charlotte, NC. IMPACT Magazine is not responsible for unsolicited manuscripts, photography or art. Products advertised are not necessarily endorsed by this publication.

advancing the business of biotechnology and life scienceELECTRICITIES Proven, Comprehensive Economic...

Documents

Transcript of advancing the business of biotechnology and life scienceELECTRICITIES Proven, Comprehensive Economic...